Aktienanalyse zu McKesson Corp (MCK)MCKMcKesson Corp

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

McKesson Corp is a strong buy at the current price of $1,004.84, especially given the recent 5-day change of +7.03% and a robust RSI of 90.185, indicating strong momentum. The forward P/E ratio of 19.72 suggests the stock is reasonably valued for its growth potential. However, the main risk is the insider selling, which has increased by 144.45% over the last month, indicating potential concerns among insiders about the stock's future performance.

14 analysts cover MCK: 4 rate it Buy, 9 Hold and 1 Sell. The average price target is 942.83.